Symbols / BCRX
BCRX Chart
About
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. It also engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 2.19B |
| Enterprise Value | 2.06B | Income | -8.78M | Sales | 599.82M |
| Book/sh | -1.84 | Cash/sh | 1.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 580 | IPO | — |
| P/E | — | Forward P/E | 10.94 | PEG | — |
| P/S | 3.65 | P/B | -4.75 | P/C | — |
| EV/EBITDA | 25.61 | EV/Sales | 3.43 | Quick Ratio | 1.60 |
| Current Ratio | 1.87 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.05 | EPS next Y | 0.80 | EPS Growth | — |
| Revenue Growth | 36.10% | Earnings | 2026-05-04 | ROA | 10.31% |
| ROE | — | ROIC | — | Gross Margin | 68.43% |
| Oper. Margin | 18.57% | Profit Margin | -1.46% | Shs Outstand | 248.04M |
| Shs Float | 182.84M | Short Float | 15.96% | Short Ratio | 8.25 |
| Short Interest | — | 52W High | 11.31 | 52W Low | 6.00 |
| Beta | 0.79 | Avg Volume | 4.36M | Volume | 10.99M |
| Target Price | $21.20 | Recom | Strong_buy | Prev Close | $7.90 |
| Price | $8.75 | Change | 10.76% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.20
Mean price target
2. Current target
$8.75
Latest analyst target
3. DCF / Fair value
$4.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.75
Low
$13.00
High
$32.00
Mean
$21.20
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-30 | main | RBC Capital | Outperform → Outperform | $13 |
| 2025-12-15 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-11-05 | main | Citizens | Market Outperform → Market Outperform | $25 |
| 2025-11-04 | main | Barclays | Equal-Weight → Equal-Weight | $9 |
| 2025-11-04 | main | Needham | Buy → Buy | $18 |
| 2025-10-15 | main | Cantor Fitzgerald | Overweight → Overweight | $26 |
| 2025-10-15 | main | JMP Securities | Market Outperform → Market Outperform | $27 |
| 2025-10-15 | main | Needham | Buy → Buy | $20 |
| 2025-08-04 | main | Needham | Buy → Buy | $17 |
| 2025-07-01 | main | B of A Securities | Buy → Buy | $15 |
| 2025-06-30 | reit | RBC Capital | Outperform → Outperform | $13 |
| 2025-06-30 | main | Wedbush | Outperform → Outperform | $18 |
| 2025-06-27 | reit | Needham | Buy → Buy | $17 |
| 2025-06-25 | reit | Needham | Buy → Buy | $17 |
| 2025-05-07 | main | Barclays | Equal-Weight → Equal-Weight | $11 |
| 2025-05-06 | reit | RBC Capital | Outperform → Outperform | $13 |
| 2025-05-06 | main | JP Morgan | Overweight → Overweight | $13 |
| 2025-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-05-06 | main | Needham | Buy → Buy | $17 |
| 2025-04-29 | init | Cantor Fitzgerald | — → Overweight | $20 |
- Are BioCryst Pharmaceuticals (BCRX) Shares Offering Value After Recent Price Rebound - Yahoo Finance Wed, 25 Feb 2026 18
- $BCRX stock is up 10% today. Here's what we see in our data. - Quiver Quantitative Fri, 27 Feb 2026 19
- BioCryst (BCRX) Soars 10.8% on Swing to Profits - Insider Monkey Sat, 28 Feb 2026 12
- BCRX SEC Filings - Biocryst Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan Fri, 27 Feb 2026 19
- Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE) - The Globe and Mail Sat, 28 Feb 2026 10
- BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates - Nasdaq hu, 26 Feb 2026 17
- BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat hu, 26 Feb 2026 15
- Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Rebound - simplywall.st Mon, 23 Feb 2026 14
- Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? - Yahoo Finance Fri, 27 Feb 2026 04
- BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Beats Expectations By $1.05 EPS - MarketBeat hu, 26 Feb 2026 18
- BioCryst Pharmaceuticals (BCRX) Profitability Surge Tests Bullish Growth Narratives - simplywall.st Fri, 27 Feb 2026 02
- BioCryst lines up March 3 slot at T.D. Cowen health care conference - Stock Titan ue, 17 Feb 2026 12
- BIOCRYST PHARMACEUTICALS ($BCRX) Releases Q4 2025 Earnings - Quiver Quantitative hu, 26 Feb 2026 13
- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat Fri, 27 Feb 2026 07
- Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition - Yahoo Finance Mon, 23 Feb 2026 21
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 14854 | — | — | Stock Award(Grant) at price 0.00 per share. | MILNE JILL C. PH.D. | Director | — | 2026-01-23 00:00:00 | D |
| 1 | 21773 | 166563 | — | Sale at price 7.65 per share. | BARNES ALANE P | Officer | — | 2025-12-22 00:00:00 | D |
| 2 | 74233 | 371896 | — | Conversion of Exercise of derivative security at price 3.22 - 5.51 per share. | GAYER CHARLES K | President | — | 2025-12-22 00:00:00 | D |
| 3 | 20000 | — | — | Stock Gift at price 0.00 per share. | STONEHOUSE JON P | Chief Executive Officer | — | 2025-12-18 00:00:00 | D |
| 4 | 121700 | — | — | Stock Award(Grant) at price 0.00 per share. | BARNES ALANE P | Officer | — | 2025-12-17 00:00:00 | D |
| 5 | 471000 | — | — | Stock Award(Grant) at price 0.00 per share. | GAYER CHARLES K | President | — | 2025-12-17 00:00:00 | D |
| 6 | 121700 | — | — | Stock Award(Grant) at price 0.00 per share. | GHIAS BABAR | Chief Financial Officer | — | 2025-12-17 00:00:00 | D |
| 7 | 21210 | 162256 | — | Sale at price 7.65 per share. | BARNES ALANE P | Officer | — | 2025-12-15 00:00:00 | D |
| 8 | 161680 | 1164967 | — | Sale at price 7.10 - 7.65 per share. | BARNES ALANE P | Officer | — | 2025-12-03 00:00:00 | D |
| 9 | 91004 | 293033 | — | Conversion of Exercise of derivative security at price 3.22 per share. | BARNES ALANE P | Officer | — | 2025-12-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -134.61K | -6.31M | -416.43K | 14.89M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | 13.45M | -86.28M | -141.87M | -176.88M |
| TotalUnusualItems | -641.00K | -30.06M | -1.98M | 55.14M |
| TotalUnusualItemsExcludingGoodwill | -641.00K | -30.06M | -1.98M | 55.14M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -88.88M | -226.54M | -247.12M | -184.06M |
| ReconciledDepreciation | 1.25M | 1.66M | 1.44M | 777.00K |
| ReconciledCostOfRevenue | 12.48M | 4.66M | 6.59M | 7.26M |
| EBITDA | 12.81M | -116.33M | -143.85M | -121.74M |
| EBIT | 11.56M | -117.99M | -145.29M | -122.52M |
| NetInterestIncome | -83.77M | -92.46M | -93.97M | -59.23M |
| InterestExpense | 98.52M | 108.24M | 99.09M | 59.29M |
| InterestIncome | 14.75M | 15.78M | 5.13M | 62.00K |
| NormalizedIncome | -88.37M | -202.79M | -245.55M | -224.32M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -88.88M | -226.54M | -247.12M | -184.06M |
| TotalExpenses | 453.25M | 435.12M | 419.26M | 334.89M |
| TotalOperatingIncomeAsReported | -2.54M | -103.71M | -148.44M | -177.72M |
| DilutedAverageShares | 206.70M | 192.20M | 185.91M | 179.12M |
| BasicAverageShares | 206.70M | 192.20M | 185.91M | 179.12M |
| DilutedEPS | -0.43 | -1.18 | -1.33 | -1.03 |
| BasicEPS | -0.43 | -1.18 | -1.33 | -1.03 |
| DilutedNIAvailtoComStockholders | -88.88M | -226.54M | -247.12M | -184.06M |
| NetIncomeCommonStockholders | -88.88M | -226.54M | -247.12M | -184.06M |
| NetIncome | -88.88M | -226.54M | -247.12M | -184.06M |
| NetIncomeIncludingNoncontrollingInterests | -88.88M | -226.54M | -247.12M | -184.06M |
| NetIncomeContinuousOperations | -88.88M | -226.54M | -247.12M | -184.06M |
| TaxProvision | 1.93M | 310.00K | 2.73M | 2.25M |
| PretaxIncome | -86.95M | -226.23M | -244.38M | -181.81M |
| OtherIncomeExpense | -641.00K | -30.06M | -1.98M | 55.14M |
| SpecialIncomeCharges | 0.00 | -29.02M | 0.00 | 55.84M |
| OtherSpecialCharges | 29.02M | -55.84M | ||
| GainOnSaleOfSecurity | -641.00K | -1.04M | -1.98M | -695.00K |
| NetNonOperatingInterestIncomeExpense | -83.77M | -92.46M | -93.97M | -59.23M |
| InterestExpenseNonOperating | 98.52M | 108.24M | 99.09M | 59.29M |
| InterestIncomeNonOperating | 14.75M | 15.78M | 5.13M | 62.00K |
| OperatingIncome | -2.54M | -103.71M | -148.44M | -177.72M |
| OperatingExpense | 440.77M | 430.46M | 412.67M | 327.63M |
| ResearchAndDevelopment | 174.64M | 216.57M | 253.30M | 208.81M |
| SellingGeneralAndAdministration | 266.13M | 213.89M | 159.37M | 118.82M |
| GrossProfit | 438.23M | 326.75M | 264.23M | 149.91M |
| CostOfRevenue | 12.48M | 4.66M | 6.59M | 7.26M |
| TotalRevenue | 450.71M | 331.41M | 270.83M | 157.17M |
| OperatingRevenue | 450.71M | 331.41M | 270.83M | 157.17M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 208.54M | 205.77M | 187.91M | 184.35M |
| ShareIssued | 208.54M | 205.77M | 187.91M | 184.35M |
| NetDebt | 691.21M | 700.62M | 428.51M | 81.07M |
| TotalDebt | 808.74M | 825.15M | 741.45M | 593.24M |
| TangibleBookValue | -475.93M | -455.53M | -294.60M | -106.99M |
| InvestedCapital | 319.99M | 355.74M | 438.68M | 478.47M |
| WorkingCapital | 261.58M | 345.98M | 410.99M | 462.42M |
| NetTangibleAssets | -475.93M | -455.53M | -294.60M | -106.99M |
| CapitalLeaseObligations | 12.82M | 13.88M | 8.17M | 7.78M |
| CommonStockEquity | -475.93M | -455.53M | -294.60M | -106.99M |
| TotalCapitalization | 319.99M | 355.74M | 438.68M | 478.47M |
| TotalEquityGrossMinorityInterest | -475.93M | -455.53M | -294.60M | -106.99M |
| StockholdersEquity | -475.93M | -455.53M | -294.60M | -106.99M |
| GainsLossesNotAffectingRetainedEarnings | 921.00K | 1.34M | 26.00K | 177.00K |
| OtherEquityAdjustments | 921.00K | 1.34M | 26.00K | 177.00K |
| RetainedEarnings | -1.77B | -1.68B | -1.45B | -1.21B |
| AdditionalPaidInCapital | 1.29B | 1.22B | 1.16B | 1.10B |
| CapitalStock | 2.08M | 2.06M | 1.88M | 1.84M |
| CommonStock | 2.08M | 2.06M | 1.88M | 1.84M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 966.35M | 972.49M | 844.60M | 695.14M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 805.97M | 822.50M | 739.08M | 591.42M |
| LongTermDebtAndCapitalLeaseObligation | 805.97M | 822.50M | 739.08M | 591.42M |
| LongTermCapitalLeaseObligation | 10.05M | 11.23M | 5.80M | 5.96M |
| LongTermDebt | 795.92M | 811.26M | 733.28M | 585.46M |
| CurrentLiabilities | 160.38M | 149.99M | 105.51M | 103.72M |
| OtherCurrentLiabilities | 32.68M | 23.57M | ||
| CurrentDeferredLiabilities | 0.00 | 1.22M | 1.42M | |
| CurrentDeferredRevenue | 0.00 | 1.22M | 1.42M | |
| CurrentDebtAndCapitalLeaseObligation | 2.77M | 2.65M | 2.37M | 1.82M |
| CurrentCapitalLeaseObligation | 2.77M | 2.65M | 2.37M | 1.82M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 48.63M | 36.52M | 22.12M | 20.67M |
| CurrentProvisions | 32.12M | 26.51M | 14.33M | 5.96M |
| PayablesAndAccruedExpenses | 44.19M | 60.75M | 65.46M | 73.85M |
| CurrentAccruedExpenses | 17.95M | 21.33M | 43.41M | 38.99M |
| Payables | 26.23M | 39.42M | 22.06M | 34.86M |
| OtherPayable | 14.59M | 18.52M | 7.70M | 4.43M |
| TotalTaxPayable | 410.00K | 2.62M | ||
| AccountsPayable | 11.64M | 20.89M | 14.36M | 27.81M |
| TotalAssets | 490.42M | 516.96M | 550.00M | 588.15M |
| TotalNonCurrentAssets | 68.45M | 20.99M | 33.50M | 22.02M |
| OtherNonCurrentAssets | 28.34M | 80.00K | 6.81M | 6.47M |
| InvestmentsAndAdvances | 20.32M | 0.00 | 18.08M | 6.83M |
| InvestmentinFinancialAssets | 6.83M | |||
| AvailableForSaleSecurities | 6.83M | |||
| NetPPE | 19.79M | 20.91M | 8.62M | 15.19M |
| AccumulatedDepreciation | -12.35M | -11.21M | -9.55M | -8.11M |
| GrossPPE | 32.13M | 32.12M | 18.17M | 23.30M |
| Leases | 10.36M | 10.21M | 10.14M | 9.83M |
| ConstructionInProgress | 97.00K | 0.00 | ||
| OtherProperties | 18.23M | 18.56M | 4.59M | 10.72M |
| MachineryFurnitureEquipment | 3.44M | 3.35M | 3.44M | 2.75M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 421.97M | 495.97M | 516.50M | 566.14M |
| OtherCurrentAssets | 13.75M | 19.54M | 12.59M | 9.99M |
| RestrictedCash | 210.00K | 1.80M | 1.47M | 3.35M |
| PrepaidAssets | 9.99M | |||
| Inventory | 8.09M | 28.68M | 27.53M | 15.79M |
| InventoriesAdjustmentsAllowances | -2.65M | -1.60M | -1.18M | -245.00K |
| OtherInventories | -23.19M | |||
| FinishedGoods | 7.76M | 6.24M | 4.81M | 709.00K |
| WorkInProcess | 16.15M | 17.59M | 14.99M | 9.67M |
| RawMaterials | 10.01M | 6.45M | 8.91M | 5.66M |
| Receivables | 79.07M | 56.95M | 50.60M | 29.41M |
| AccountsReceivable | 79.07M | 56.95M | 50.60M | 29.41M |
| CashCashEquivalentsAndShortTermInvestments | 320.85M | 388.99M | 424.31M | 507.60M |
| OtherShortTermInvestments | 216.14M | 278.34M | 119.54M | 3.21M |
| CashAndCashEquivalents | 104.71M | 110.64M | 304.77M | 504.39M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -53.14M | -97.31M | -163.20M | -144.54M |
| RepaymentOfDebt | -1.70M | -241.62M | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 300.00M | 73.07M | 293.87M |
| IssuanceOfCapitalStock | 34.00K | 342.00K | 190.00K | 50.06M |
| CapitalExpenditure | -1.12M | -2.17M | -1.35M | -2.38M |
| InterestPaidSupplementalData | 30.38M | 22.14M | 0.00 | 900.00K |
| IncomeTaxPaidSupplementalData | 1.60M | 1.43M | 3.54M | 118.00K |
| EndCashPosition | 106.32M | 112.45M | 306.24M | 507.73M |
| BeginningCashPosition | 112.45M | 306.24M | 507.73M | 274.35M |
| EffectOfExchangeRateChanges | -936.00K | 362.00K | 566.00K | 71.00K |
| ChangesInCash | -5.19M | -194.15M | -202.06M | 233.31M |
| FinancingCashFlow | -5.76M | 32.48M | 88.03M | 359.67M |
| CashFlowFromContinuingFinancingActivities | -5.76M | 32.48M | 88.03M | 359.67M |
| NetOtherFinancingCharges | -7.54M | -34.58M | 293.87M | |
| ProceedsFromStockOptionExercised | 3.44M | 8.34M | 14.77M | 15.73M |
| NetCommonStockIssuance | 34.00K | 342.00K | 190.00K | 50.06M |
| CommonStockIssuance | 34.00K | 342.00K | 190.00K | 50.06M |
| NetIssuancePaymentsOfDebt | -1.70M | 58.38M | 73.07M | 293.87M |
| NetShortTermDebtIssuance | 73.07M | 0.00 | ||
| ShortTermDebtPayments | 0.00 | 0.00 | ||
| ShortTermDebtIssuance | 73.07M | 0.00 | ||
| NetLongTermDebtIssuance | -1.70M | 58.38M | 73.07M | 293.87M |
| LongTermDebtPayments | -1.70M | -241.62M | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 300.00M | 73.07M | 293.87M |
| InvestingCashFlow | 52.59M | -131.50M | -128.24M | 15.80M |
| CashFlowFromContinuingInvestingActivities | 52.59M | -131.50M | -128.24M | 15.80M |
| NetInvestmentPurchaseAndSale | 53.72M | -129.33M | -126.89M | 18.19M |
| SaleOfInvestment | 320.48M | 385.08M | 117.40M | 28.20M |
| PurchaseOfInvestment | -266.76M | -514.41M | -244.28M | -10.01M |
| NetPPEPurchaseAndSale | -1.12M | -2.17M | -1.35M | -2.38M |
| PurchaseOfPPE | -1.12M | -2.17M | -1.35M | -2.38M |
| OperatingCashFlow | -52.02M | -95.14M | -161.85M | -142.16M |
| CashFlowFromContinuingOperatingActivities | -52.02M | -95.14M | -161.85M | -142.16M |
| ChangeInWorkingCapital | -87.28M | -32.40M | -58.95M | 8.12M |
| ChangeInOtherWorkingCapital | -1.23M | -109.00K | 1.28M | |
| ChangeInPayablesAndAccruedExpense | -62.38M | -16.81M | -22.36M | 43.58M |
| ChangeInAccruedExpense | 0.00 | 0.00 | 4.17M | |
| ChangeInInterestPayable | 0.00 | 0.00 | 4.17M | |
| ChangeInPayable | -62.38M | -16.81M | -22.36M | 39.41M |
| ChangeInAccountPayable | -62.38M | -16.81M | -22.36M | 39.41M |
| ChangeInPrepaidAssets | 1.96M | -6.82M | -2.58M | -7.16M |
| ChangeInInventory | -4.16M | -1.45M | -12.42M | -8.77M |
| ChangeInReceivables | -22.70M | -6.09M | -21.47M | -20.82M |
| OtherNonCashItems | 67.61M | 85.80M | 98.92M | 54.20M |
| StockBasedCompensation | 65.41M | 55.62M | 44.70M | 34.64M |
| AssetImpairmentCharge | 1.35M | 1.97M | 932.00K | 0.00 |
| AmortizationOfSecurities | -11.47M | -10.26M | -1.78M | -2.00K |
| DepreciationAmortizationDepletion | 1.25M | 1.66M | 1.44M | 777.00K |
| DepreciationAndAmortization | 1.25M | 1.66M | 1.44M | 777.00K |
| Depreciation | 1.25M | 1.66M | 1.44M | 777.00K |
| OperatingGainsLosses | 29.02M | -55.84M | ||
| NetIncomeFromContinuingOperations | -88.88M | -226.54M | -247.12M | -184.06M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BCRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|